COMMUNIQUÉS West-GlobeNewswire

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
20/08/2024
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new [...]
TerrAscend Announces $10 Million Share Repurchase Program
20/08/2024
TORONTO, Aug. 20, 2024 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF) , a leading North American cannabis company, today announced that its Board of Directors has [...]
Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak
20/08/2024
Roche is committed to supporting all those working to overcome the mpox outbreak by providing access to high-quality Polymerase Chain Reaction (PCR) testing Roche confirms that its cobas MPXV test, as well as the [...]
SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System
20/08/2024
SANTA CLARA, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510( [...]
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
20/08/2024
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential of Ampligen and two other drugs OCALA, Fla [...]
NeuroStar® Marks Two Years of Transformative Impact with NeuroStar University
20/08/2024
Celebrating milestones in patient care and practice enhancement through NeuroStar’s innovative training facility MALVERN, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology [...]
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
20/08/2024
CORAL GABLES, Fla., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and [...]
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
20/08/2024
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The [...]
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
20/08/2024
SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive [...]
Nanox Announces Second Quarter of 2024 Financial Results and Provides Business Update
20/08/2024
Accelerated the deployment of Nanox ARC in the US market, Submitted a new 510k application to the FDA to expand Nanox.ARC indications to include general use, including chest Nanox.AI Receives FDA 510K Clearance for [...]
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
20/08/2024
JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that [...]
Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024
20/08/2024
Media Release Oral presentation will detail results from the randomized TACTI-003 Phase IIb trial in first line head & neck squamous cell carcinoma patients with any PD-L1 expression (CPS > 1) SYDNEY, AUSTRALIA, [...]
Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension
20/08/2024
DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of results of a post [...]
Opus Genetics Receives Rare Pediatric Disease Designation from the U.S. FDA for Ocular Gene Therapy OPGx-LCA5 to Treat Rare Inherited Retinal Disease LCA5
20/08/2024
Priority Review Voucher would be issued upon approval of OPGx-LCA5 RESEARCH TRIANGLE PARK, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first, clinical-stage gene therapy company developing [...]
Incyclix Bio Appoints Dr. Andrew Beelen as Vice President of Clinical Development
20/08/2024
RESEARCH TRIANGLE PARK, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of [...]
LAVA Reports Second Quarter 2024 Financial Results and Business Update
20/08/2024
Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combination Favorable safety profile for LAVA-1207 Next data update [...]
The Joint Corp. to Participate in the 7th Annual B. Riley Securities Consumer & TMT Conference
20/08/2024
SCOTTSDALE, Ariz., Aug. 20, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic ® network , announced that management plans to [...]
Infectious Disease Expert Kelly Warfield Named Sabin’s New R&D President
20/08/2024
caption: Sabin Vaccine Institute Research & Development President Kelly Warfield WASHINGTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Virologist and vaccine development leader Kelly Warfield has joined the Sabin Vaccine [...]
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication
20/08/2024
CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department More than 27,569 individuals in the U.S. died from drug overdose deaths involving cocaine [...]

Pages